SkinBioTherapeutics plc (AIM: SBTX)
London flag London · Delayed Price · Currency is GBP · Price in GBX
16.75
-0.75 (-4.29%)
Dec 20, 2024, 3:55 PM GMT+1

SkinBioTherapeutics Company Description

SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally.

It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development.

The company has an agreement with Croda Plc for the development of SkinBiotix as an active ingredient for the skicare/cosmetic industry.

It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets.

The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016.

SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.

SkinBioTherapeutics plc
Country United Kingdom
Founded 2015
Industry Biotechnology
Sector Healthcare
Employees 15
CEO Stuart Ashman

Contact Details

Address:
The Core
Newcastle upon Tyne, NE4 5TF
United Kingdom
Phone 44 19 1495 7325
Website skinbiotherapeutics.com

Stock Details

Ticker Symbol SBTX
Exchange London Stock Exchange AIM
Fiscal Year July - June
Reporting Currency GBP
ISIN Number GB00BF33H870
SIC Code 2844

Key Executives

Name Position
Stuart Ashman Chief Executive Officer
Manprit Randhawa Chief Financial Officer